Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

This phase II trial studies the side effects and how well Vyxeos works in treating patients with intermediate and high-risk acute myeloid leukemia who have failed an initial cycle of standard cytarabine and daunorubicin chemotherapy. Vyxeos is a combination of both chemotherapy drugs cytarabine and daunorubicin contained in a liposome. Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cytarabine and daunorubicin given togethe

Trial Details

NCT ID
NCT04049539
Phase
PHASE1 / PHASE2
Sponsor
Ohio State University Comprehensive Cancer Center
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Liposome-encapsulated Daunorubicin-Cytarabine
Locations (sample)
  • Sacramento, California, United States|38.58157,-121.4944
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Subject must be able to provide written informed consent
  • Patients must have a diagnosis of acute myeloid leukemia
  • Patients must have received standard induction chemotherapy (cytarabine 100-200mg/m2 by continuous infusion on days 1-7 and either daunorubicin 45-…
  • Patients must be deemed by the treating physician to be unlikely to achieve complete response (CR) without further therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →